P=N/A, N=50, Recruiting, Uşak University

P=N/A, N=160, Recruiting, Uşak University | Not yet recruiting --> Recruiting

P3, N=561, Recruiting, Galderma R&D | Not yet recruiting --> Recruiting

P=N/A, N=52, Active, not recruiting, Cairo University

We report the case of a 37-year-old female with psoriasis who, after achieving stable disease control on ixekizumab, developed widespread eruptive brown macules, patches, and papules within one month of receiving a quadrivalent HPV vaccine...The lesions faded following oral acitretin therapy...We discuss potential mechanisms, propose clinical management considerations, and provide insights that may inform future research and clinical practice. The ultimate aim is to contribute to the refinement of guidelines on vaccination in patients receiving biologic therapy for psoriasis, ensuring both therapeutic efficacy and patient safety.

P2/3, N=351, Terminated, Laurent Pharmaceuticals Inc. | N=125 --> 351 | Completed --> Terminated; Phase 2 completed normally, Phase 3 terminated for futility due to lack of aggravation events.

P1, N=18, Active, not recruiting, Dwight Owen | Suspended --> Active, not recruiting | Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Oct 2025 --> Jan 2026

Previous treatment with topical corticosteroids, Calcipotriol Betamethasone Ointment and acitretin provided poor control of psoriasis, resulting in significant quality-of-life impairment. Xeligekimab demonstrated significant efficacy and acceptable safety over 28 weeks in this complex case of psoriasis with concurrent hidradenitis suppurativa, chronic hepatitis B, and metastatic colorectal cancer. Extended follow-up is ongoing to evaluate long-term outcomes, while larger prospective studies are warranted to validate biologic therapy for such multimorbid presentations.

P2, N=15, Completed, Island Pharmaceuticals | Active, not recruiting --> Completed

P1, N=18, Suspended, Dwight Owen | Recruiting --> Suspended

P=N/A, N=200, Recruiting, Bausch Health Americas, Inc. | Not yet recruiting --> Recruiting

Systemic retinoids, particularly acitretin, have demonstrated efficacy in reducing epidermal hyperkeratosis and enhancing clinical outcomes...Distinctive diagnostic clues-such as very early disease onset, autosomal recessive mode of inheritance, and the hallmark transgradient pattern of palmoplantar keratoderma-can aid in distinguishing MDM from the more prevalent psoriasis vulgaris. Although biologic therapies targeting TNF-α and IL-17A have shown limited efficacy in MDM, systemic retinoids continue to represent a clinically effective therapeutic option for managing this rare genodermatosis.